RJA
BIVV

Raymond James & Associates’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Raymond James & Associates’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-149,772
Closed -$8.07M – 3659
2017
Q4 		$8.07M Sell
149,772
-20,852
-12% -$1.14M 0.01% 877
2017
Q3 		$9.74M Buy
170,624
+26,080
+18% +$1.53M 0.02% 757
2017
Q2 		$8.7M Buy
144,544
+1,237
+0.9% +$70.4K 0.02% 771
2017
Q1 		$7.8M Buy
+143,307
New +$7.06M 0.02% 802

Other funds holding BIVV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
ACS
Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

Raymond James & Associates's BIVV Position: Q1 2018 in Review

Raymond James & Associates sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 149,772 shares — an estimated $8.07M sold.

Raymond James & Associates first reported a position in BIVV in Q1 2017 and held it in 4 quarters. The position peaked at $9.74M in Q3 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

  • Raymond James & Associates reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Raymond James & Associates sold 149,772 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $8.07M.
  • Raymond James & Associates first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 4 quarters.
  • Raymond James & Associates's Bioverativ Inc. Common Stock position peaked at $9.74M in Q3 2017.
  • 2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on Raymond James & Associates's 13F filing for Q1 2018, filed 14 May 2018.